IL6 and triple-A syndrome: In this regard, these analyses were largely limited to European genetic ancestry populations, although previous work supports that similar associations may hold in other genetic ancestry populations.49 Furthermore, these genetic analyses evaluated the risk of developing AAA but do not directly assess the clinical impact of reduced IL6 signaling after AAA has already manifested, the clinical setting in which AAA therapies would actually be applied.